• Chia-Jung Kuo, Puo-Hsien Le, Wei-Chen Tai, Keng-Liang Wu, Hsu-Heng Yen, Chih-Wei Yen, Shui-Yi Tung, Chen-Shuan Chung, Ming-Yao Su, and Cheng-Tang Chiu.
• Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou, Taiwan; Chang Gung University, College of Medicine, Taoyuan, Taiwan; Taiwan Association for the Study of Small Intestinal Disease, Taiwan; Chang Gung Microbiota Therapy Center, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
• J Formos Med Assoc. 2022 Sep 1; 121 (9): 1689-1695.

BackgroundThe use of biologic agents has become the cornerstone of therapy for moderate to severe IBD. Few studies have investigated the efficacy of vedolizumab (VDZ) induction for ulcerative colitis (UC) in Asian patients in a real practice setting.AimsTo evaluate the efficacy and safety of VDZ induction therapy for moderate to severe UC in Taiwan.MethodsThis was a retrospective and observational study. Selected moderate to severe UC patients received VZD 300 mg i.v. at weeks 0, 2, and 6 as induction therapy. Mayo scores were calculated to evaluate the efficacy.ResultsA total of 37 patients with UC who received VDZ and completed the induction therapy at Chang Gung Memorial Hospital (2017/10-2021/5) were included. The mean age was 46.5 year-old and the male to female ratio was 1:1 (19/18). 81.8% of the patients were biologic-naive. At weeks 8-10, a clinical response, clinical remission and endoscopic remission with VDZ induction therapy were achieved in 56.8% (21/37), 32.4% (12/37) and 58.3% (7/12) of the patients, respectively. 54.1% (20/37) were able to taper off at week 8. Overall, only 10.8% (4/37) of the patients were primary non-responders during induction therapy. No obvious VDZ-related severe adverse events were noted. Overall, 58.9% (11/19) of the patients relapsed after stopping VDZ, and the relapse rate after VDZ discontinuation was 42.1% (8/19) within first 6 months and 52.6% (10/19) within the first year.ConclusionIn real-world experience, induction therapy with VDZ showed promising clinical benefits and safety profile for patients with UC.Copyright © 2021 Formosan Medical Association. Published by Elsevier B.V. All rights reserved.

14 keywords...

hide…